Krystal Biotech (NASDAQ:KRYS) Insider Suma Krishnan Sells 25,000 Shares of Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) insider Suma Krishnan sold 25,000 shares of the company’s stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the transaction, the insider owned 1,378,155 shares of the company’s stock, valued at approximately $424,623,337.05. This represents a 1.78% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Krystal Biotech Stock Down 2.2%

Shares of KRYS traded down $6.79 during mid-day trading on Friday, reaching $301.00. 264,305 shares of the stock traded hands, compared to its average volume of 291,307. The stock has a fifty day simple moving average of $281.47 and a 200 day simple moving average of $263.93. Krystal Biotech, Inc. has a 12-month low of $127.99 and a 12-month high of $319.48. The firm has a market cap of $8.87 billion, a price-to-earnings ratio of 40.24 and a beta of 0.53.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, May 4th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.45 by $0.38. Krystal Biotech had a net margin of 53.92% and a return on equity of 19.25%. The business had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, equities research analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of KRYS. Seven Fleet Capital Management LP boosted its holdings in shares of Krystal Biotech by 7.9% in the 1st quarter. Seven Fleet Capital Management LP now owns 4,316 shares of the company’s stock valued at $1,115,000 after buying an additional 316 shares during the period. Western Wealth Management LLC acquired a new stake in Krystal Biotech during the first quarter worth about $34,000. Bank of America Corp DE raised its stake in Krystal Biotech by 36.6% during the first quarter. Bank of America Corp DE now owns 260,647 shares of the company’s stock worth $67,330,000 after acquiring an additional 69,840 shares during the period. Janus Henderson Group PLC lifted its holdings in Krystal Biotech by 21.5% in the first quarter. Janus Henderson Group PLC now owns 266,659 shares of the company’s stock worth $68,879,000 after acquiring an additional 47,219 shares during the last quarter. Finally, Cim LLC bought a new position in Krystal Biotech in the first quarter worth about $3,872,000. 86.29% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms recently commented on KRYS. Weiss Ratings upgraded Krystal Biotech from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, April 9th. Wolfe Research assumed coverage on Krystal Biotech in a report on Friday, March 27th. They set a “peer perform” rating on the stock. Citigroup upped their target price on Krystal Biotech from $371.00 to $378.00 and gave the company a “buy” rating in a research report on Tuesday, May 5th. Guggenheim raised their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research report on Wednesday, February 25th. Finally, Chardan Capital lifted their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Ten investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, Krystal Biotech has a consensus rating of “Moderate Buy” and an average target price of $324.11.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.